Leerink Downgrades Illumina to Market Perform on Near-Term Growth Uncertainties | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Leerink lowered its rating on Illumina's stock to Market Perform from Outperform, citing uncertainty about the growth potential of the company's next-generation sequencing products in the research market and a "less compelling" risk-reward profile on the company's stock at current levels, Leerink analyst Dan Leonard wrote in a note.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.